NYSE
$1.50▼ 0.99%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $47.1MShares out 31.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 10.16After-hours26.10.17 06:114Ownership#●●●
Actinium Pharmaceuticals, Inc.
Insider David Matthew T of Actinium Pharmaceuticals, Inc. reported a change in beneficial ownership of securities as of October 14, 2026. This filing is a standard Form 4 disclosure regarding insider stock transactions.…more
$1.50-0.99%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.16After-hours26.10.17 06:103Ownership
Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. insider David Matthew T has filed a Form 3 to report his initial statement of beneficial ownership of securities. This filing serves as the official disclosure of the insider's equity holdings.…more
$1.50-0.99%vs prev closeView filingShare - 10.16Pre-market26.10.16 20:51ARSOther
Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. has filed its Annual Report to Security Holders (ARS) for the fiscal year ended December 31, 2025. This filing provides comprehensive information regarding the company's financial condition and business operations.…more
$1.50-0.99%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoPre-market26.10.23 21:05#●●●#●●●#●●●
Actinium Pharma to Present Phase 1 Data for ATNM-400 at ESMO 2026
Actinium Pharmaceuticals will present the first-in-human Phase 1 study results of its HER3-targeted radiotherapy, ATNM-400, for metastatic castration-resistant prostate cancer at the ESMO Congress 2026. The study highlights a differentiated approach targeting HER3 to potentially address treatment resistance in solid tumors.…more
$1.50-0.99%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 4d agoRegular26.10.21 02:11
●●●●●●●● ●●●●● ●●●●●●
Actinium Pharmaceuticals shares rose after reporting encouraging initial safety data from its Phase 1 trial of ATNM-400 for prostate cancer. The company successfully cleared the first dose-escalation cohort with no significant adverse events observed.…more
$1.50-0.99%vs prev closeShareBenzinga - 4d agoPre-market26.10.20 20:32
●●●●●●●● ●●●●● ●●●●●●
Actinium Pharmaceuticals announced new preclinical results demonstrating the antitumor potential of ATNM-400 across various cancer models at the EANM congress. As these findings are from early-stage research without clinical trial outcomes or revenue impact, the news is considered neutral.…more
$1.50-0.99%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report